Dermatology Search
Dermatology Dermatology
alopecia
ALOPECIA

Alopecia is an involuntary loss of hair usually in the scalp that may occur anywhere over the body.
Scarring alopecia is severe inflammation of the hair follicle result in irreversible damage.
Non-scarring alopecias are reversible.
Alopecia may  be abrupt or gradual in onset.
Most common causes include androgenic alopecia (male & female pattern baldness) & alopecia areata.
History should be reviewed for medications, severe diet restriction, vitamin A supplementation, thyroid symptoms, concomitant illness & stress factor.

Drug Information

Indication: Rheumatic fever, RA, allergic diseases, nephritic syndrome, bronchial asthma & other corticosteroid-indica...

Indication: Replacement therapy for acute adrenocortical insufficiency eg, Addison's disease, bilateral adrenalectomy; rel...

Indication: RA, acute gouty arthritis, bronchial asthma, serum sickness, lupus, nodular arthritis, allergic dermatitis, pe...

Indication: Stimulates hair growth & stabilizes hair loss in patients w/ alopecia androgenetica.

Indication: Allergic, collagen, dermatological, GI, desquamative gingivitis, hematologic, tuberculous meningitis, ophth, r...

Indication: Bronchial asthma, allergic disease, RA, juvenile RA, rheumatoid myocarditis, rheumatic myelitis, psoriasis, os...

Indication: Men w/ pattern hair loss (androgenetic alopecia).

Shincort
triamcinolone acetonide

Indication: RA, synovitis, allergic rhinitis, asthma, allergic dermatitis, pemphigus, allergic & inflammatory ophth di...

Indication: Primary or secondary adrenocortical insufficiency; endocrine, rheumatic, collagen, dermatologic, ophth, resp, ...

1  /  3
1  /  3
Editor's Recommendations
Most Read Articles
Clindamycin shows promise as alternative treatment to antibiotics in hidradenitis suppurativa
25 Apr 2019
A recent study has demonstrated the potential of clindamycin as a treatment alternative to antibiotic combination regardless of hidradenitis suppurativa (HS) clinical stage.
Original New Drug Application Approvals by US FDA (16 - 30 April 2019)
01 May 2019
New drug applications approved by US FDA as of 16 - 30 April 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.